Results 1 to 10 of about 13,503 (207)

The potential of lymphocyte–C-reactive protein ratio upon admission to predict therapeutic responsiveness to mesalazine in adult patients with mild-to-moderate active ulcerative colitis [PDF]

BMC Gastroenterology
Objective This study aimed to investigate the potential of lymphocyte-to-C-reactive protein ratio (LCR) upon admission to predict therapeutic responsiveness to mesalazine in adult patients with mild-to-moderate active ulcerative colitis (UC).
Chen Liu, Yan Zhang, Ya-Jun Wang, Yu-Jia Tang, Yue Yang, Chun-Hui Gu, Yi-Lu Lin, Yao Li, Jia-Le Deng, Jia-Xi Xu, Jia-Ning Zhang, Na Zhan, Bo-Wen Liu, Kai Kang, Yang Gao   +14 more
doaj   +2 more sources

Late‐Onset Mesalazine‐Induced Eosinophilic Pneumonitis Presenting as Non‐Resolving Pneumonia: A Diagnostic Pitfall in Ulcerative Colitis [PDF]

Clinical Case Reports
Mesalazine is widely used in the management of ulcerative colitis and is generally well tolerated. Rarely, it can cause eosinophilic pneumonitis, a potentially serious form of drug‐induced lung injury that often mimics infection.
Siraj Nasim, Tamer Mohamed Zaalouk, Abu Bocus, Maged Kerols   +3 more
doaj   +2 more sources

Mesalazine Regulates DUSP1, DUSP4, and DUSP5 Expression in Colorectal Cancer: In Vitro and Bioinformatic Evidence [PDF]

Pharmaceutics
Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide, with its development closely linked to dysregulation of mitogen-activated protein kinase (MAPK) signaling pathways. Background: Dual-specificity phosphatases
Marcel Madej, Ilona Nowak, Barbara Strzałka-Mrozik, Magdalena Kimsa-Dudek, Celina Kruszniewska-Rajs, Joanna Magdalena Gola   +5 more
doaj   +2 more sources

Clinical effects of ursodeoxycholic acid on patients with ulcerative colitis may improve via the regulation of IL-23-IL-17 axis and the changes of the proportion of intestinal microflora

The Saudi Journal of Gastroenterology, 2021
Background: We aimed to evaluate the therapeutic effect of additional ursodeoxycholic acid (UDCA) with mesalazine, compared to mesalazine alone in patients with ulcerative colitis (UC). The mechanism was evaluated by monitoring the changes of IL-23-IL-17
Zhengjun Wang, Jinhua Chen, Zhiping Chen, Longke Xie, Wen Wang   +4 more
doaj   +1 more source

Comparative evaluation of the effectiveness of monotherapy of ulcerative colitis with mesalazine MMX and combination therapy with non-prolonged mesalazines with rectal forms

Медицинский совет, 2022
Introduction. According to clinical guidelines, the treatment of patients with ulcerative colitis (UC) is carried out as combination therapy with mesalazine in rectal forms.The aim was to compare the effectiveness of treatment of moderate severity UC ...
O. V. Knyazev, A. V. Kagramanova, A. A. Lishchinskaya, A. F. Babaian, T. V. Shkurko, B. A. Nanaeva, I. A. Li   +6 more
doaj   +1 more source

Preformulation and preliminary formulation studies of mesalazine gastro-resistant tablets [PDF]

Romanian Journal of Pharmaceutical Practice, 2020
Mesalamine, 5-aminosalicylic acid or mesalazine is the standard therapy of inflammatory bowel disease. A small number of pharmaceutical dosage forms with mesalazine are on the market.
Adriana Aurelia Chiş, Isabela Crăciun, Carmen Maximiliana Dobrea, Felicia Gabriela Gligor, Angela Bărbat, Luca Liviu Rus   +5 more
doaj   +1 more source

Evaluation of the efficacy of MMX mesalazine therapy for moderate ulcerative colitis

Медицинский совет, 2021
Introduction. Treatment of patients with ulcerative colitis (UC) requires continuous anti-relapse therapy. Mesalazines are the firstline disease-modifying drugs for the treatment of mild to moderate UC to manage exacerbations and to induce and maintain ...
O. V. Knyazev, A. V. Kagramanova, A. A. Lishchinskaya   +2 more
doaj   +1 more source

Efficacy and safety of Qingre-Chushi therapies in active ulcerative colitis: A network meta-analysis.

PLoS ONE, 2021
BackgroundUlcerative colitis (UC) is a chronic inflammatory disease with an increasing incidence in the world. Qingre-Chushi therapies (QC) can alleviate clinical symptoms.
Ling Zhang, Yun-Bo Wu, Yun-Kai Dai, Qi Liu, Yu-Jie Ren, Shi-Jie Xu, Huai-Geng Pan, Wei-Jing Chen, Ru-Liu Li, Ling Hu   +9 more
doaj   +1 more source

A Case Report and Literature Review of Mesalazine-Induced Kidney Injury in a Pediatric Patient With Ulcerative Colitis

Frontiers in Pediatrics, 2022
BackgroundMesalazine, a preparation of 5-aminosalicylic acid, is a medication widely used in clinical practice as a first-line therapy in the treatment of mild and moderate inflammatory bowel disease.
Shuo Wang, Pengxiang Zhou, Zailing Li
doaj   +1 more source

Comparative Transcriptomic Analysis Reveals the Immunosuppressive Targets of Mesalazine in Dextran Sulfate Sodium-Induced Ulcerative Colitis

Frontiers in Genetics, 2021
Ulcerative colitis (UC) is a complex inflammatory bowel disorder that can induce colonic and rectal dysfunction. Mesalazine, a first-line medicine, is routinely prescribed for UC treatment.
Rong Li, Lin Cheng, Qi Wang, Liming Zhou
doaj   +1 more source